In the all-adalimumab cohort ( n = 79 ) , clinical remission rates were approximately 30 % after 36weeks of exposure to adalimumab and for the remainder of the study ( 35 % , 33 % , and 28 % for weeks 48 , 108 , and 144 , respectively ) .